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A dissolution method with robust high performance liquid chromatographic (HPLC) analysis for im-
mediate release tablet formulation was developed and validated to meet the requirement as per Inter-
national Conference on Harmonization (ICH) and United States Food and Drug Administration (USFDA)
guidelines. The method involved the use of Agilent ZORBAX Eclipse XDB C18 column, and temperature
was maintained at 30 °C. After optimization, the mobile phase was selected as phosphate buffer (KH2PO4,
30 mM) : ACN (60:40, v/v) with pH 3.0, and retention time Rt was found as 3.24, 4.16, and 2.55 min for
paracetamol (PCM), chlorpheniramine maleate (CPM) and phenylephrine hydrochloride (PH) respec-
tively at 265 nm and at a ﬂow rate of 1 mL/min. The relative standard deviation (%RSD) for 6 replicate
measurements was found to be less than 2%. Furthermore net analyte signal standard addition method
(NASSAM) with spectrophotometer was performed for standard and liquid oral suspension. On the basis
of selectivity, sensitivity and accuracy analysis, it was conﬁrmed that this novel method could be useful
for simultaneous estimation of the given drug combinations. Two-way analysis of variance (ANOVA) was
applied for evaluating the statistical difference between the assay results obtained via both NASSAM and
RP–HPLC methods and ultimately no signiﬁcant difference was found between both the methods. All the
methods and results were acceptable and conﬁrmed that the method was suitable for intended use.
& 2014 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
High performance liquid chromatography (HPLC) method plays
an important role in dissolution testing (DT) procedures. It pro-
vides a wide dynamic linear range, selectivity via separation and
superior sensitivity. These features have been used to solve a
variety of analytical problems encountered during DT of complex
drug delivery systems. The linear range for an HPLC method occurs
typically up to many orders of magnitude. The wide dynamic
range often allows us to conduct the DT of formulation doses
ranging from 0.1 to 200 mg with a single HPLC method. HPLC
method also affords superior sensitivity over direct spectro-
photometric method and is often used for DT of drug products
with very low potencies [1].
The method has been validated to ensure that they are suitable
for their intended use and give accurate and precise data. DT playson and hosting by Elsevier B.V. All
University.
x: þ91 16 3623 9515.
rma),an important role in acquiring product sameness under scale up
and post approval changes (SUPAC) related change. For solid do-
sage form, the characteristics of dissolution under physiological
condition inﬂuence in vitro dissolution. Solubility, permeability of
drug products and release products (immediate/ extended) are the
major factors which affect the dissolution of development and
quality control (QC) of synthetic as well as herbal drugs. The value
of DT enhances signiﬁcantly when performance of drug substance
is evaluated as a function of time. DT is useful in QC and produc-
tion batch to ensure similarities, so the DT remains similar and is
crucial for clinical trial batches; further dissolution proﬁling is
used to support bioavailability and bioequivalence of a new
pharmaceutical product [2].
This manuscript described the development and subsequent
validation of methods via reverse phase high performance liquid
chromatography (RP–HPLC) and net analyte signal standard ad-
dition method (NASSAM) and further applicability of the devel-
oped RP–HPLC method in DT of tablet formulation containing
PCM, CPM and PH as active ingredients in combination. Method
robustness is an essential parameter that should be studied and
evaluated carefully [3].rights reserved. This is an open access article under the CC BY-NC-ND license
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thogonal to the space of other compounds (interferants) is known
as NAS. It can be directly correlated to the analyte concentration in
standard addition method. Therefore, the analyte concentrations
can be determined simultaneously from a unique standard addi-
tion plot. NASSAM, as a new analysis method, is simple for esti-
mating a drug with high precision and accuracy. It also requires no
additional sample preparation. Hence, it can be a powerful and
substituted method in comparison with HPLC for analysis of
multiple components in simple steps [4].
Nowadays, NASSAM procedure has been widely applied alone
or in conjugation with various sophisticated analytical methods,
including DT of cocrystal forms [5]. Other recent examples include
simultaneous determination of sulphadiazine and trimethoprim in
bovine milk and veterinary medicines [6], determination of sul-
famethoxazole and trimethoprim in pharmaceutical formulations
and biological ﬂuids [7] and antazoline and naphazoline de-
termination with NASSAM and spectrophotometric methods [8].
Simultaneous estimation is the analysis of standards present in
multiple combination dosage form at the same time period. The
advantages of simultaneous estimation lie in that it can avoid time
consuming extraction and separation, and minimize the use of
expensive reagents. And the method is further accurate and
precise.
PCM, N-(4-hydroxyphenyl) acetamide [9] (Fig. 1), acts by in-
hibiting cyclo-oxygenase (COX-3, a linked variant of COX-1). It is an
analgesic and antipyretic and used along with various cold pre-
parations [10].
CPM, (3RS)-3-(4-Chlorophenyl)-N,N-dimethyl-3-(pyridin-2-yl)
propan-1-amine hydrogen (Z)-butenedioate [9] (Fig. 1), is an an-
tihistamine which has lower sedative effects than other anti-
histamines [10].
PH, (1R)-1-(3-hydroxyphenyl)-2-(methylamino) ethanol hy-
drochloride [9] (Fig. 1), is a selective α1-adrenergic receptor agonist
used primarily in nasal decongestion, as an agent to dilate the
pupil and to increase blood pressure [10].
All three drugs are ofﬁcial in Indian pharmacopoeia (IP) [11] and
British Pharmacopoeia (BP) [9]. The PCM, CPM and PH alone or in
combination with other drugs are reported to be estimated by the
spectrophotometric method [12–15], derivative spectrophotometric
method [16], chemometric-assisted spectrophotometry [17], HPLC
[18,19], thin layer chromatography (TLC) [20], liquid chromatography–
mass spectrometry (LC–MS) [21], Fourier transform infrared spectro-
scopy (FT–IR) [22], amperometric determination [23], ﬂuorimetry [24],
micellar electrokinetic chromatographic method [25], electrophoresis
[26], liquid chromatography with two ultraviolet (UV) absorbance
detectors [27], and chemometric determination [28].
Literature survey revealed that HPLC method was reported for
this combination [29] but DT was not reported for tablets con-
taining PCM, CPM and PH by robust RP–HPLC method. Further-
more, NASSAM was not available for this combination, which is a
new, sensitive, economical and reliable analytical technique forN
H
O
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N
N
Cl
Paracetamol Chlorpheniramine m
Fig. 1. Chemical structures of paracetamol, chlorphenirsimultaneous estimation of multicomponent mixtures. The pre-
sent study mainly aimed at developing a DT procedure by devel-
oped RP–HPLC method for determination of PCM, CPM and PH in
tablet dosage form, and further included analysis of signiﬁcant
difference between the HPLC and NASSAM via two-way ANOVA.2. Materials and methods
2.1. Materials
HPLC grade acetonitrile (ACN), potassium di-hydrogen phos-
phate buffer (KH2PO4), orthophosphoric acid (OPA) and hydro-
chloric acid (HCl) were purchased from Rankem (New Delhi, In-
dia). HPLC grade water for chromatography and dissolution [ob-
tained from water puriﬁcation systems Milli-Q, ELIX 03 (MILLI-
PORE, Milford, MA, USA)] was used. Solutions were ﬁltered
through a qualisil nylon syringe ﬁlter (25 mm0.45 mm) Ultipors
N66
s
and membrane ﬁlter (47 mm0.45 mm) (Pall Pvt. Ltd., India)
prior to use. Standards of PCM, CPM and PH were procured from
Syncom Health Care (Dehradun, India). Marketed formulation
named as SNEEZY tablets was labeled as each uncoated tablet
contained 500 mg of PCM, 5 mg of PH and 2 mg of CPM (quinoline
yellow) batch no. SC12030, manufactured by Cadila Pharmaceu-
ticals, and COLD-GO which is an oral suspension was labeled as
each 5 mL of oral suspension contained 125 mg of PCM, 2 mg of
CPM and 25 mg of PH (having coloring agent ponceau4R) batch no.
HG-278, manufactured by Torque Pharmaceutical Limited, which
was procured from local market (Moga, Punjab, India).
2.2. Instruments
HPLC system fromWATERS (Milford, USA) is equipped with 515
HPLC pump as a solvent delivery system, rheodyne injection valve
with a 20 mL loop and WATERS 2998 photodiode array (PDA) de-
tector set at a wavelength range of 190–400 nm. Separation was
performed on an Agilent ZORBAX Eclipse XDB “C18” column
(4.6 mm150 mm, 5 mm). Chromatographic data were recorded
and processed using EMPOWER-2 software.
Dissolution system from LABINDIA Disso 2000 is equipped with
high precision multichannel pump and sample collector. For
weighing analytical balance (Mettler Toledo and Sartorius) and pH
measurement, pH meter (Mettler Toledo) was used. HPLC grade
water was obtained from water puriﬁcation systems, Milli-Q, ELIX
03 (MILLIPORE, Milford, MA, USA).
UV-vis double beam spectrophotometer Perkin-Elmer Lambda-
35 was used for all spectrophotometric measurements (i.e., for
NASSAM), having a slit width of 1 nm, installed with UV-Winlab
and UV-Winlab data processor and viewer software. All spectra
were saved in comma separated ﬁle (CSV) format and then data
were statistically analyzed using unscramble 10.2.OH
OH
O
O
HO N
HOH
.HCl
aleate Phenylephrine
hydrochloride
amine maleate and phenylephrine hydrochloride.
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Pure samples stock solutions (1 mg/mL) of PCM, CPM and PH
were freshly prepared in 0.1 M HCl, and further dilutions were
made using mobile phase which was selected as 30 mM phosphate
buffer (KH2PO4) : ACN (60:40, v/v), with pH adjusted to 3.0 with
OPA. For solid dosage form analysis, 20 tablets were weighed and
triturated to obtain ﬁne powder. Stock solution was prepared in
0.1M HCl and further dilution was made with mobile phase.
Standard addition method was performed in order to increase the
concentration of CPM and PH in marketed formulation. The stan-
dard solutions of CPM and PH (10 mg/mL) were prepared by di-
luting the suitable aliquots of stock solution with 0.1 M HCl and
further with mobile phase, and aliquots of spiking solution were
spiked to marketed dilutions. For preparation of test samples (for
oral suspension), solution was ﬁrst extracted in 0.1 M HCl using
sonication process for 1 h at room temperature. After this process,
the resultant solution was ﬁltered through syringe ﬁlter. Then
further dilutions were made in mobile phase and processed for
HPLC method.
For preparation of samples for NASSAM, stock solution was
prepared in methanol, and further dilutions were made in diluting
solvent, i.e., methanol : 0.1 M HCl (1:9, v/v). For preparation of
samples for interference matrix, 15 aliquots were prepared for
PCM, CPM and PH (based on the linearity range for PCM, CPM and
PH). Further the norms [i.e., determination of sum of square of
obtained data (X) and then square root of X component] were
calculated by exporting the scanned spectra into CSV format. Si-
milarly, 15 aliquots of standard mixture were prepared as shown in
Table 1. For calculating the interference matrices for PCM, mixture
of CPM and PH was prepared within their linearity range, and the
same procedures were applied for CPM and PH. For standard ad-
dition mixtures, tertiary mixture dilutions were prepared, keeping
two drugs' concentrations constant on linearity basis. The same
procedures were applied for CPM and PH. Finally we got 30 ali-
quots (15 for interference matrices and 15 for standard addition
method matrices).
2.4. Methods
2.4.1. Optimization of chromatographic conditions
In order to achieve the best chromatographic separation, we
changed different experimental variables. Finally, the appropriate
conditions for method validation were selected. On the basis of
system suitability parameters, i.e., resolution factor (Rs), peak
tailing factor (Tf), symmetry, retention time (Rt), capacity factor (k′)
and height equivalent theoretical plates (HETP), the optimized
chromatograms were selected for PCM, CPM and PH. The optimi-
zation parameters were signiﬁcantly affected by the mobile phase
composition (type and composition of organic modiﬁers/aqueous
phase pH of solution, ﬂow rate, column temperature andTable 1
Aliquots concentrations of all three drugs used in interference matrix and standard add
Set Interference matrix concentration (mg/mL) Standa
PCM CPM PH PCM
PH CPM PCM PH PCM CPM PCM
I 9 5 1.5 9 1.5 5 1.5
II 18 10 3 18 3 10 3
III 36 20 6 36 6 20 6
IV 52 30 12 52 12 30 12
V 64 40 15 64 15 40 15wavelength). Further, these parameters were changed to achieve
the best system suitability parameters. Various trials have been
done in the above optimized parameters individually or in com-
bination. To achieve the proper separation, various conditions
were applied, which include mobile phase composition, i.e.,
phosphate buffer (KH2PO4) (20, 25, 30 and 35 mM) : ACN in dif-
ferent ratios (55:45, 40:60, 60:40, 65:35, 45:55 and 70:30, v/v) at
different pH (2, 3 and 4), column temperatures (25, 30 and 35 °C),
ﬂow rates (0.8, 1 and 1.2 mL/min) and wavelengths (262, 265 and
268 nm).
2.4.2. Effect of change in mobile phase composition
Different ratios of mobile phases (buffer KH2PO4 and ACN)
(55:45, 40:60, 60:40, 65:35, 45:55 and 70:30, v/v) and different
molarities of aqueous phase (20, 27, 30 and 33 mM) were used.
The optimized peak was resolved at (30 mM) phosphate buffer:
ACN (60:40) with satisfactory Rs, Tf, HETP and symmetry. In an-
other composition we found variable deviations from standard
value for all SST parameters as shown in Fig. 2(C), (F), and (I).
2.4.3. Effect of change in pH
Optimizations were performed by varying the pH (2.7, 3 and
3.3) of aqueous phase (KH2PO4), while the other factors were kept
constant. Number of theoretical plates (n), Rs, k′, Tf and HETP were
found optimum for method development at 3 pH. The Rs was
decreased for both PCM and CPM with increase in HETP at pH
2.7 and 3.3 as shown in Fig. 2(B), (E), and (H).
2.4.4. Effect of change in ﬂow rates
Various ﬂow rates were tried (0.8, 1 and 1.2 mL/min) that af-
fected the Rt of drugs. By increasing the ﬂow rate, the Rt was de-
creased and vice versa. HETP was found highest at 1.2 and 0.8 mL/
min. At 0.8 mL/min, Tf was found to be 42 for PCM. Finally the
ﬂow rate 1 mL/min was selected, while other parameters were
kept constant. Effects of ﬂow rates for PCM, CPM and PH are
shown in Fig. 2(A), (D), and (G).
2.4.5. Effect of change in column oven temperatures
Various column oven temperatures (27, 30 and 33 °C) were
employed. At 27 °C, merging of PCM and CPM occurred with
Rso2, and at 33 °C, peak broadening and increase in HETP value
occurred for CPM. Finally, 30 °C was selected as optimized column
oven temperature for study, at which all SST parameters were
found to be superlative.
2.5. Finalized chromatographic conditions after optimization
After analyzing all robustness parameters and optimization
conditions, the recommended condition was the mobile phase
consisting of phosphate buffer (KH2PO4, 30 mM) : ACN (60:40, v/v)
with pH 3. The chromatograms after optimization showedition matrix.
rd addition matrix concentration (mg/mL)
CPM PH
CPM PH PCM CPM PH PCM CPM PH
10 9 6 5 9 6 10 9
10 9 6 10 9 6 10 18
10 9 6 20 9 6 10 36
10 9 6 30 9 6 10 52
10 9 6 40 9 6 10 64
Fig. 2. Optimization graphs for PCM (A, B and C ), CPM (D, E and F) and PH (G, H and I) in which x axis indicates the ﬂow rate (mL/min), pH and buffer molarity (mM).
Primary y axis indicates tailing factor (Tf), resolution (Rs), capacity factor (K′), symmetric factor (Sf), and secondary y axis indicates height equivalent theoretical plates (HETP).
Fig. 3. Chromatogram of PCM, CPM and PH after ﬁnal optimization.
Y. Upadhyay et al. / Journal of Pharmaceutical Analysis 5 (2015) 307–315310symmetric and sharp peak with the Rt of 3.24, 4.16 and 2.55 min
for PCM, CPM and PH respectively as shown in Fig. 3. The best
resolution and sensitivity of the method were obtained at 265 nm
at a ﬂow rate of 1 mL/min and column oven temperature of 30 °C.2.6. Dissolution test (DT) conditions
The DT was performed in compliance with United States
Pharmacopoeia (USP) (711) using apparatus 2 with paddles. For
optimization of medium and paddle, speeding of a dissolution
medium/agitation screening was performed. After optimization,
medium was selected as 0.1 M HCl (having a pH of 1.8 gastro-
intestinal tract). Because the tablets were uncoated and disin-
tegrated immediately in gastrointestinal tract, 0.1 M HCl was se-
lected as a dissolution medium. The performances of dissolution
apparatuses are highly dependent on hydrodynamics which in-
cludes coning and may affect the dissolution study. In order to
minimize coning, paddle speed was optimized as 50 rpm. Media
volume of 900 mL was ﬁlled in six baskets and two baskets were
used as blank for replenishing. The medium, before processing,
was degassed via sonication process, and temperature was set at
3770.5 °C. At different time intervals (0–150 min), samples were
drawn off (n¼6, samples were drawn off at each time interval).
Due to the immediate releasing property of these tablets, the
earlier time intervals provided more distinguished ability. Auto-
samplings were performed and samples were ﬁltered through
syringe ﬁlters.
Fig. 4. Vector space for analyte (PCM) and other analytes (CPM and PH) in two
dimensions.
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Method validation was performed after getting optimized peak.
Isocratic elution was done using 1 mL/min ﬂow rate with phos-
phate buffer (KH2PO4, 30 mM) : ACN (60:40, v/v) at pH 3 (adjusted
with OPA). Fresh mobile phases were prepared for each analysis.
Before introducing into the system, the mobile phase was ﬁltered
through 0.45 mm membrane ﬁlters and degassed through soni-
cator. Pre-UV scanning (380–180) was done and ﬁnal wavelength
was selected as 265 nm for all estimations, because UV detection
in this wavelength provided the optimal sensitivity needed for
excellent quantiﬁcation of the low drug concentration of marketed
formulation. To achieve the equilibrium, the column was saturated
at least 30 min before the analysis. The substances were quantiﬁed
using peak area ratio.
2.8. NASSAM method
NAS technique is deﬁned as the net analyte signal for an analyte
as a part of its spectrum which is orthogonal to the space spanned
by the spectra of all other analytes. It is given by the following
equation [4,30]:
⎡⎣ ⎤⎦P D Y Y A B 1k kS NAS, kA( )= – = ( )⁎ +
where Y denotes the I J matrix having calibration response of I
samples at J sensors, A is the spectrum of given sample (spectrum
Ck of pure k at unit concentration) and number of spectra used to
build the model, D is the J J identity matrix, Yk is a J L column
spaced spanned by the spectra of all other analytes except that k
[(Yk)þ is the pseudo inverse of Yk, L is the number of spectral
factors used to build the model], and BNAS, k is the J J NAS space.
The standard addition method was used to eliminate the cali-
bration and prediction steps of multivariate calibrations method
and determination was carried out in a single step for each ana-
lyte. For simultaneous estimation by this technique, it required
spectrum vector of mixtures. The standard concentrations of PCM,
CPM and PH were simultaneously added to the sample solutions.
The spectrum was recorded after each standard addition based on
the following equations:
A D E D E D E 20
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0
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0
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0
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0
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0
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0
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0
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0
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where A0 and Ai are the absorbances of the synthetic mixture
before and after standard addition, respectively. E0PCM, E0CPM, E0PH
and E0PCM, si, E0CPM, si and E0PH, si are initial added concentrations of
PCM, CPM and PH, respectively.
NAS vector (Fig. 4) for PCM, CPM and PH compounds after each
standard addition, NASPCM, NASCPM, and NAS PH can be found from
the following equation, respectively:
I R R ANAS 6iPCM = ( – ) ( )+
I S S ANAS 7iCPM = ( – ) ( )+
I T T ANAS 8iPH = ( – ) ( )+
where I denotes identical matrix, R, S and T are the matrices of
absorbances at different concentrations of both interferences ac-
cording to Table 1. In Rþ , Sþ , and Tþ , the superscript (þ) denotesthe pseudoinverse of R, S, and T matrices respectively. The
spectrum of mixture Ai is a combination of two independent parts
NASPCM, orthogonal to space of interferences (CPM and PH) and
(RþR), Ai is generated by linear combination of the spectra of
interfering agents and it denotes standard addition matrix as
shown in Table 1.3. Results and discussion
3.1. Validation
Linearity, range, accuracy, robustness, limit of detection (LOD),
limit of quantiﬁcation (LOQ), selectivity and sensitivity were useful
validation parameters for comparison of methods as well as for
determination of quality of given spectral analytical techniques [3].
3.1.1. Calibration and linearity
HPLC standard mixtures were prepared for all three drugs in
their linearity range, and calibration curve was plotted. Samples
were injected in triplicate (validation parameters are shown in
Table 2). The retention time of standards was 3.24 min for PCM,
4.16 min for CPM and 2.55 min for PH. A typical HPLC chromato-
gram of the standard mixtures is shown in Fig. 3. Then peak area
against the concentration of the drugs was plotted to obtain the
calibration graphs. These calibration graphs were found to be
linear in the stated range. For NASSAM the calibration graphs were
obtained by calculating norms of interference matrix data sets. For
NASSAM and RP–HPLC methods correlation coefﬁcients for PCM,
CPM and PH were found to be 0.997oR2o1. Overlay chromato-
gram and calibration curve obtained via HPLC methods are shown
in Fig. 5. NAS overlay spectra for PCM, CPM and PH are shown in
Figs. 6A, 7A, and 8A, respectively.
3.1.2. Precision
The inter-day and intra-day precision parameters were studied
for all the drugs (n¼3). The percent relative standard deviation
was calculated, which was found to be less than 2% for all drugs,
indicating that the method was reliable and reproducible. The
precision data are shown in Table 3.
3.1.3. Assay and recovery studies
The recovery tests were performed by adding the known
amount of each standard drug in suspension as well as tablets. The
Table 2
Validation parameters obtained by all methods.
Method Drugs λmax (nm) Range (mg/mL) Regression equation Correlation coefﬁcient (R2) LOD (mg/mL) LOQ (mg/mL) Selectivity Sensitivity (mL/mg)
RP–HPLC PCM 265 0.5517.6 y¼16282x472.4 0.9970 0.41 1.31 – 0.41
CPM 265 1.444.8 y¼6795x2312 0.9990 1.19 3.51 – 1.19
PH 265 1.651.2 y¼4008xþ1597 0.9970 1.47 5.77 – 1.47
NASSAM PCM 320-210 1.515 y¼0.131x0.011 0.9980 0.38 1.28 0.18 0.83
CPM 320-210 540 y¼0.027x0.033 0.9980 1.56 5.14 0.10 1.37
PH 320-210 964 y¼0.027x0.031 0.9970 2.36 7.78 0.13 1.02
Fig. 5. Overlay chromatogram of PCM, CPM and PH.
Fig. 6. (A) NAS spectrum for PCM, (B) overlapped spectra for CPM and (C) overlapped
spectra for PH.
Fig. 7. (A) NAS spectrum for CPM, (B) overlapped spectra for PH, and (C) overlapped
spectra for PCM.
Fig. 8. (A) NAS spectrum for PH, (B) overlapped spectra for PCM, and (C) overlapped
spectra for CPM.
Table 3
Precision data obtained via RP–HPLC method for all drugs.
Drugs Concentration (mg/mL) % RSD (Mean7SD)
Intra-day Inter-day
PCM 1.1, 4.4, 17.6 0.9070.06 1.1170.20
CPM 2.8, 11.2, 44.8 0.9170.11 1.2470.14
PH 3.2, 12.8, 51.2 0.7470.03 0.9470.21
Table 4
Assay of marketed formulations.
Method Obtained (%) (Mean7SD)
PCMa CPMb PHc
RPHPLC
(Suspensionn) 98.5170.44 98.2370.02 98.3670.12
RPHPLC (Tabletsnn) 99.1870.86 98.6070.63 99.3071.13
NASSAM (Suspensionn) 99.870.14 99.7370.18 98.9470.05
Suspension: PCM: 125 mg, CPM: 2 mg, PH: 25 mg; Tablet: PCM: 500 mg, CPM:
2 mg, PH: 5 mg.
a*Paracetamol suspension contains not less than 95.0% and not more than 105.0%
(w/v) solution of the stated amount of paracetamol.
a **Paracetamol tablet contains not less than 95.0% and not more than 105.0% (w/v)
solution of the stated amount of paracetamol.
b Chlorpheniramine suspension contains not less than 95.0% and not more than
105.0% of the stated amount of chlorpheniramine maleate.
b **Chlorpheniramine tablet contains not less than 95.0% and not more than 105.0%
of the stated amount of chlorpheniramine maleate.
c *Phenylephrine suspension contains not less than 95.0% and not more than 105.0%
of the stated amount of phenylephrine hydrochloride.
c **Phenylephrine tablet contains not less than 95.0% and not more than 105.0% of
the stated amount of phenylephrine hydrochloride.
Y. Upadhyay et al. / Journal of Pharmaceutical Analysis 5 (2015) 307–315312same procedure was applied for NASSAM for estimating suspen-
sion. Results having excellent recoveries were obtained. Assay of
marketed formulation was done and is shown in Table 4. Recovery
Table 5
Recovery studies results for oral suspension dosage form by RP–HPLC and NASSAM.
Concentration (μg/mL) Recovery (%) (m/m)
RP–HPLC NASSAM
PCM CPM PH PCM CPM PH PCM CPM PH
8 0.064 0.32 97.51 98.18 98.08 98.54 98.64 99.94
10 0.080 0.40 98.69 97.68 99.30 101.03 101.71 99.55
12 0.096 0.48 98.14 99.79 100.30 97.73 102.34 102.20
Mean recovery (%) 98.21 98.47 99.01 99.11 100.93 99.11
SD 0.59 1.10 1.11 1.73 2.00 1.43
Table 6
Recovery studies results for tablet dosage form by RP–HPLC method.
Concentration (μg/mL) Recovery (%) (m/m)
PCM CPM PH PCM CPM PH
8 0.032 0.08 99.07 99.79 100.42
10 0.040 0.10 100.73 99.70 101.30
12 0.048 0.12 98.81 98.72 98.76
Mean recovery (%) 99.45 99.20 99.94
SD 1.04 0.59 1.28
Table 7
System suitability parameters for all drugs.
Parameters PCM CPM PH Limits [3]
Capacity factor (k) 1.55 2.04 2.16 1–10
Theoretical plates 3793.24 3386.51 3844.13 42000
Resolution (Rs) 2.085 2.384 – 42
Tailing factor (Tf) 1.43 1.51 1.55 r2
Symmetric factor 1.53 1.64 1.61 (Depend upon peak tailing.
1:1)
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6, respectively, and the concentrations shown in Table 4 and Table
5 were obtained after subtracting the standard added
concentrations.
3.1.4. LOD and LOQ
LOD was the concentration of analyte that produces analytical
signal equal to thrice the deviation of background signals. The LOQ
was the lowest amount of analyte which could be quantiﬁed.
These parameters were studied for both methods.
For NASSAM, LOD is estimated by the following equation:
XLOD 3 / NAS 9Ti= || || || || ( )
where X denotes the measure of measurement errors. This can be
estimated by calculating the norms of several blank samples
(n¼10). NASTi is the net analyte signal of T component [4,30,31].
Data obtained via NASSAM and RP–HPLC methods are shown in
Table 2.
3.1.5. Selectivity and sensitivity
In simple deﬁnition selectivity refers to a method that produces
a response of a single analyte. No interference was observed, re-
sulting from the substance present in formulation. Sensitivity re-
fers to as the response due to a particular analyte varies as a
function of its concentration. In RP–HPLC method, one can directly
select the sensitivity value equivalent to LOD value because as per
deﬁnition sensitivity is also known as minimum detectable con-
centration of analyte. But for NASSAM, we can easily calculate the
sensitivity of the analyte using Eq. (10), and due to a large number
of spectral data and human errors, sometimes, sensitivity values
are deviated from LOD value as shown in Table 2.
Orthogonal spectra refers to spectra with no overlap had se-
lectivity equal to 1, whereas identical spectra have selectivity equal
to zero [4,30,31]. Practically, in NASSAM, we have a large number
of test samples, which lead to human errors as well, and for this
reason, selectivity is not always equal to zero. As suggested by
Garner [32], selectivity and sensitivity were calculated in two
different ways, i.e. multivariate ﬁgures of merit by using analytical
blanks in which 10 different blanks of diluting solvent werescanned, and analytical signals obtained were used to generate the
NAS norms; the second method includes use of NAS obtained from
samples with low concentration, ﬁxing near to the lower limit of
the linear range and variable concentrations of the other ones in
all the ranges shown in the calibration sets.
By NASSAM, these parameters are calculated as
Selectivity NAS / Ti 10Ti= || || || || ( )
Sensitivity NAS 11Ti= || || ( )
where NASTi is the net analyte signal of T component and Ti de-
notes the total signal of T components [31]. Data for these
parameters are shown in Table 2.
3.1.6. System suitability parameters
The system suitability parameters were estimated for precise
method development. These parameters were found within the
speciﬁed limits and are shown in Table 7.
3.1.7. Robustness and ruggedness
The factors which affect the peak symmetry are percentage
organic/aqueous mobile phase, ﬂow rate, temperature and wave-
length. For this study, the symmetry was found to be consistently
less than 1.64 across all the studies. So the suitability of method
did not affect with respect to peak symmetry. Further, the 10%
variations were done for all parameters as shown in Fig. 2. The
ﬂow rates and % organic phases affected the peak efﬁciency and
retention time. The aim of robustness study was to ﬁnd an actual
value for organic phase composition, ﬂow rate, pH and tempera-
ture for this method.
Ruggedness is essential to performing as per USFDA guidelines.
It is deﬁned as reproducibility of an analytical method obtained by
the analysis of same sample under different variable conditions
like different laboratories, analysts, instruments, and environ-
mental conditions. The test results obtained in terms of %RSD were
found to be less than 2%. Results obtained via robustness and
ruggedness studies are shown in Table 8.
3.1.8. Percentage drug release
At different time intervals [0, 5, 10, 15, 30, 60, 90, 120 and
150 min (n¼6, samples were drawn off at each time interval)], the
release rate of tablet dosage form having PCM, CPM and PH was
noted. Retention time was found to be 3.24, 4.16 and 2.55 min for
PCM, CPM and PH, respectively. Overlay chromatogram obtained
at various time intervals is shown in Fig. 9. Data obtained with the
approximately same retention time were found excellent percen-
tage drug release rate and are shown in Table 9.
3.2. Signiﬁcant difference between RP–HPLC and NASSAM via two-
way ANOVA
Two-way ANOVA is an appropriate analysis method for a study
with a quantitative outcome of two (or more) categorical ex-
planatory variables. Here we have applied this statistical technique
Table 8
Robustness and ruggedness data obtained from RP–HPLC method for all drugs.
Parameters Variable Drugs
(% RSD) (Mean7SD)
PCM CPM PH
Molarities concentration
(mM)
27 1.0870.43 1.3870.91 1.0770.59
30 0.9470.64 0.7970.17 0.7870.48
33 1.0870.25 1.7070.43 0.9170.48
pH 2.7 1.1570.33 1.0370.54 0.8370.39
3.0 0.9470.64 0.7970.17 0.7870.48
3.3 1.1770.16 0.9770.15 0.9870.82
Temperature (°C) 27 1.0070.04 1.3270.89 1.4370.45
30 0.9470.64 0.7970.17 0.7870.48
33 1.4370.56 1.4970.21 1.3870.42
Flow rate (mL/min) 0.8 1.1170.75 0.9170.14 1.0170.13
1 0.9470.64 0.7970.17 0.7870.48
1.2 0.9270.56 1.4470.50 1.2770.49
Mobile phase composition
(phosphate buffer:
acetonitrile)
54:46 1.6570.12 0.9970.14 0.9970.90
60:40 0.9470.64 0.7970.17 0.7870.48
66:34 1.0470.50 1.4570.63 1.2870.51
Wavelength (nm) 262 1.3170.57 1.0170.33 1.0370.47
265 0.9470.64 0.7970.17 0.7870.48
268 1.6270.33 1.4170.14 1.3070.72
Column Agilent 0.9470.64 0.7970.17 0.7870.48
Waters 1.0970.67 0.8470.48 1.5870.56
Analyst Analyst 1 0.9470.64 0.7970.17 0.7870.48
Analyst 2 1.0170.39 1.1970.74 1.2070.48
Fig. 9. Overlay chromatogram obtained via dissolution method at various time
intervals.
Table 9
Percentage drug release at different time intervals for PCM, CPM and PH.
Time (min) % Drug release7SD (n¼6)
PCM CPM PH
5 27.870.81 22.871.01 17.370.59
10 43.970.79 35.470.58 33.370.51
15 51.570.73 61.070.73 66.170.70
30 61.570.89 73.470.69 67.770.65
60 69.170.63 76.170.38 76.270.53
90 83.170.50 80.270.82 82.771.11
120 99.270.59 97.770.30 97.771.04
150 99.470.68 98.370.27 98.570.43
Table 10
Assay data used in two-way ANOVA for statistical comparison between RP–HPLC
and NASSAM for oral suspension.
Method Assay (%, w/w)
PCM CPM PH
RP–HPLC 98.35 98.21 98.26
99.31 98.28 98.24
98.26 98.21 98.35
98.31 98.23 98.47
98.32 98.24 98.51
Mean7SD 98.5170.44 98.2370.02 98.3670.12
NASSAM 99.67 99.61 98.91
99.92 99.87 98.92
99.84 99.98 98.9
99.97 99.55 98.95
99.64 99.67 99.03
Mean7 SD 99.8070.14 99.7370.18 98.9470.05
Table 11
Two-way ANOVA results obtained via comparing assay data of RP–HPLC and
NASSAM for oral suspension.
Source of
variation
Sum of
squares
Degree of
freedom
Mean
square
F-value P-value (at
0.05 level of
signiﬁcance)
F-critical
Rows 9.80 9 1.08 9.91 0.0000241 2.45
Columns 1.31 2 0.65 5.99 0.0101 3.55
Error 1.97 18 0.10
Total 13.09 29 F-value 4 F-Critical
P-value o 0.05
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SAM) for combined oral suspension as shown in Table 10. Results
were satisfactory and found within the limits. Calculated values
were less than the theoretical value. At 0.05 level of signiﬁcance P-
value was found to be less than 0.05 and F-value was found to be
less than F-critical value at the same signiﬁcance level of analysis,
which indicates that there is no signiﬁcant difference betweenboth the methods. Two-way ANOVA results obtained via com-
paring assay data of RP–HPLC and NASSAM for oral suspension are
shown in Table 11.4. Conclusion
The optimization of RP–HPLC method showed that the mobile
phase composition, pH and ﬂow rate were more crucial para-
meters to be controlled for reproducible and quantitative estima-
tion of PCM, CPM and PH. Simple and reproducible sample ex-
traction for oral suspension provided higher sensitivity for de-
termination of tertiary combination of drugs by RP–HPLC and
NASSAM. The developed RP–HPLC method could further be ap-
plicable to bio-analytical method development, stability indicating
method or in vitro–in vivo correlation studies for this particular
combination.
The validated developed RP–HPLC and NASSAM were found
simple, speciﬁc, accurate, rapid, precise, economical and reliable
for contemporary analysis of drugs in tablet form as well as oral
suspension. Validation parameters for this particular situation
were adequate for both methods. Dissolution procedure was per-
formed to characterize the drug release rate for tablet dosage form
and further analyzed by developed RP–HPLC method. Successfully
two-way ANOVA was applied (in assay results) between RP–HPLC
and NASSAM for analysis of oral suspension. Further, it was con-
cluded that there was no signiﬁcant difference between both the
methods. The dissolution and simultaneous estimation procedure
could be applied to routine quality control analysis of oral sus-
pension as well as solid dosage form.
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